Skip to content
May 4, 2026

Aktis Oncology Initiates Phase 1b Clinical Trial for AKY-2519, in Metastatic Castration-Resistant Prostate Cancer (mCRPC)

You are about to leave MPM BioImpact's website. MPM BioImpact is not responsible for the content on other companies' websites.

Cancel Continue